摘要
背景:帕金森病(PD)是一种慢性进行性疾病,是世界上第二常见的神经退行性疾病。经典特征包括:运动迟缓,静息震颤。r,刚性和溃烂。这些神经改变可能是由于黑质致密部多巴胺能神经元死亡和多巴胺输入减少所致。纹状体。多巴胺水平的降低也可能与非运动症状的出现有关,包括认知障碍、焦虑和抑郁症状。神经营养因子(NF)Ar调节神经元功能、发育和存活的蛋白质。据报道,NF可能在PD中发挥保护作用。 目的:探讨临床前和临床研究中有关神经营养因子(NF)在帕金森病(PD)中的作用及其作为有前途的治疗策略的潜力的新证据。 方法:在PubMed中心进行广泛的文献检索。 结果:应用NF治疗PD的临床前研究可能由于方法上的差异而存在差异,从而排除了任何结论。与行政管理有关的临床研究结果NF在PD患者中的浓度更令人失望。另一方面,临床前和临床上的研究普遍支持体力活动是一种低成本、非药理学的策略。治疗PD效果良好。 结论:应用NF治疗帕金森病仍是一项尚未纳入临床实践的承诺。注射NFS的方法、剂量和化合物、副作用、种群特征抽搐和病程可能导致不成功的结果。
关键词: 帕金森病,神经营养因子,BDNF,GDNF,MPTP,6-OHDA.
Current Medicinal Chemistry
Title:Neurotrophic Factors in Parkinson’s Disease: What Have we Learned from Pre-Clinical and Clinical Studies?
Volume: 25 Issue: 31
关键词: 帕金森病,神经营养因子,BDNF,GDNF,MPTP,6-OHDA.
摘要: Background: Parkinson´s Disease (PD) is a chronic, progressive condition, being the second most common neurodegenerative disorder worldwide. The classical features include: bradykinesia, resting tremor, rigidity and festination. These neurological alterations are probably due to the death of dopaminergic neurons in the Substantia Nigra pars compacta and consequent reduction of dopamine input into the striatum. The decrease of dopamine levels may also be involved in the emergence of non-motor symptoms, including cognitive impairment, anxiety and depression symptoms. Neurotrophic Factors (NF) are proteins that modulate neuronal function, development, and survival. It has been reported that NF might exert a protective role in PD.
Objective: We aim to discuss the emerging evidence from pre-clinical and clinical studies regarding the role of NF in PD as well as their potential as promising therapeutic strategies.
Methods: We carried out an extensive literature search in PubMed central.
Results: Pre-clinical studies using NF to treat PD are divergent probably due to several methodological differences, thus precluding any conclusion. Clinical studies findings obtained with the administration of NF in patients with PD were even more disappointed. On the other hand, pre-clinical and clinical studies generally support that physical activity is a low-cost, non-pharmacologic strategy with good results to treat PD.
Conclusion: The use of NF as a treatment for PD is still a promise not incorporated in clinical practice. Methods to deliver NFs, doses and compounds administered, side effects, population characteristics and duration of disease may probably contribute to the unsuccessful results.
Export Options
About this article
Cite this article as:
Neurotrophic Factors in Parkinson’s Disease: What Have we Learned from Pre-Clinical and Clinical Studies?, Current Medicinal Chemistry 2018; 25 (31) . https://dx.doi.org/10.2174/0929867325666180313101536
DOI https://dx.doi.org/10.2174/0929867325666180313101536 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reversible and Irreversible Aggregation of Proteins from the FET Family: Influence of Repeats in Protein Chain on Its Aggregation Capacity
Current Protein & Peptide Science A Translational View of Peptide Treatment of Neurological Disorders
Current Medicinal Chemistry Designing of Novel Carbonic Anhydrase Inhibitors and Activators
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Pathophysiology of Heme in the Brain
Current Alzheimer Research Diabetes Mellitus to Neurodegenerative Disorders: Is Oxidative Stress Fueling the Flame?
CNS & Neurological Disorders - Drug Targets Aqueous Extract of <i>Cola nitida</i> and <i>Garcinia kola</i> Synergistically Enhances Hippocampal-hypothalamic Glutamate and Na+ /K+ -ATPase Activity in Male Wistar Rats
Current Drug Discovery Technologies Molecular Mechanism Aspect of ER Stress in Alzheimer's Disease: Current Approaches and Future Strategies
Current Drug Targets The Role of Adenosine in Alzheimers Disease
Current Neuropharmacology Inflammatory Mediators in Epilepsy
Current Pharmaceutical Design G Protein - Mediated Signaling: Same Receptor, Multiple Effectors
Current Molecular Pharmacology Ligands Targeting the Excitatory Amino Acid Transporters (EAATs)
Current Topics in Medicinal Chemistry Targeting Exocytosis: Ins and Outs of the Modulation of Quantal Dopamine Release
CNS & Neurological Disorders - Drug Targets Overlapping the Tryptophan Catabolite (TRYCAT) and Melatoninergic Pathways in Alzheimer's Disease
Current Pharmaceutical Design Neurotrophic Factors for Retinal Ganglion Cell Neuropathy - With a Special Reference to Diabetic Neuropathy in the Retina
Current Diabetes Reviews Anti-Amyloid Aggregating Gold Nanoparticles: Can they Really be Translated from Bench to Bedside for Alzheimer's Disease Treatment?
Current Protein & Peptide Science Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes
Current Chemical Biology Monoamine Oxidase Inhibitors: Perspective Design for the Treatment of Depression and Neurological Disorders
Current Enzyme Inhibition Potential Beneficial Effects of Marine Peptide on Human Neuron Health
Current Protein & Peptide Science Bacterial Protein Toxins: Current and Potential Clinical Use
Current Medicinal Chemistry Genetically-Modified Human Pluripotent Stem Cells: New Hopes for the Understanding and the Treatment of Neurological Diseases?
Current Gene Therapy